Stockreport

Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer

Genmab A/S - American Depositary Shares  (GMAB) 
PDF Phase 1/2 RAINFOLâ„¢-01 data showed the combination of rinatabart sesutecan (Rina-S®) and bevacizumab was tolerable, with no new safety signals in patients with advanced o [Read more]